Halma Share Price (HLMA)

.wealthoracle.co.uk/company-results

Halma has agreed to acquire Strasbourg-headquartered Dreampath Diagnostics for an initial €154m (approximately £132m) cash, funded from existing facilities, with a further €121m (£104m) earn-out payable over performance periods to March 2027 and March 2028 — taking maximum consideration to €275m (£236m). Dreampath is the leading provider of automated tissue sample tracking, storage and lifecycle management systems for anatomical pathology laboratories, with revenue for the 12 months to March 2027 forecast at €33m (£28m). That implies an initial revenue multiple of around 4.7x and a full-consideration multiple close to 8.4x — punchy but consistent with Halma's discipline of paying up for high-quality, defensible healthcare assets with structural tailwinds. The strategic fit is clean: Dreampath combines hardware, software and recurring consumables in a closed system, addressing regulatory mandates that require patient samples be retained for a minimum of ten years, and slots neatly alongside Halma's existing Healthcare Enablement portfolio. The business will operate standalone under its current management within the Healthcare Sector, preserving the decentralised model that underpins Halma's compounder credentials. Earn-out weighting toward 2028 (62%) aligns vendor incentives with growth delivery. For a Group whose Healthcare Sector has faced tougher comparatives recently, the addition of a recurring-revenue diagnostics platform in an ageing-demographic end market is a constructive capital deployment and reinforces the bolt-on M&A engine that remains central to Halma's long-run compounding story.

.wealthoracle.co.uk/company-results

.wealthoracle.co.uk/company-results

Halma has deployed roughly £54m of cash on two bolt-on healthcare acquisitions, extending its serial-acquirer playbook into hospital digitalisation and precision oncology. The FTSE 100 group is paying €23m (around £20m) for Dutch business itemedical, a specialist in digital platforms that aggregate real-time patient data and device alarms to streamline hospital workflows, which will slot into subsidiary SSG. Alongside, it is paying $45m (around £34m) for Sweden's Naslund Medical, whose Gold Anchor fiducial marker technology enables more precise tumour targeting in radiotherapy, complementing IZI Medical's existing Visicoil platform. Both deals are on a cash- and debt-free basis and funded from existing facilities, leaving balance sheet headroom untouched in any meaningful way. On revenue, the targets are modest — itemedical generated €7.8m (about £7m) in the twelve months to March 2026 and Naslund $9.2m (about £7m) over the same period — implying combined revenue multiples in the mid-to-high single digits, punchy but consistent with Halma's stated appetite to pay up for niche, high-margin healthcare assets with international runway. Neither deal moves the needle on group numbers in isolation, but they reinforce the compounding thesis: bolt-ons into structural growth pockets, delegated operating model, disciplined capital allocation. With hospital digitalisation budgets firming and radiation oncology volumes expanding globally, management will look to leverage Naslund's existing international footprint to accelerate IZI's overseas expansion over the coming financial year.

.wealthoracle.co.uk/company-results

Sp tapped on into weekly demand block of 30/3/26, high price 3924. The demand block has provided bullish liquidity to fuel the current daily price rally. The bearish weekly supply block which caused the intervening price fall, is above 4600, which can be used as a suitable price target.

The sector has a bullish ratio of 10/2 for risers and fallers. DYOR.

Another broker raises sp target 15/06/26 - Exane BNP raises Halma to 'outperform' - price target 4550p

The company lost 15% of something (the shareholders) before it happens. So when the profits drop next year the price will drop again, we take a double drop. The share price should follow the results of the company and not follow what someone may think may happen. What happend was manipulation at the highest level. Its getting to the point that everything is corrupt in this country.

All we did was transfer 15%